Scheen Aj
Impact in
-
- Diabetes Treatment and Management
- Hormonal Regulation and Hypertension
- Diabetes, Cardiovascular Risks, and Lipoproteins
-
- Blood Pressure and Hypertension Studies
- Renin-Angiotensin System Studies
Papers in
-
- Diabetes Treatment and Management 18
- Diabetes Management and Research 10
- Pharmacology 10
- Pharmacology and Obesity Treatment 9
- Co-authors
- Nicolas Paquot (5 shared papers)Marcelle Rorive (3 shared papers)Nicolas Paquot (3 shared papers)Michel Letiexhe (1 shared paper)Philippe Schneiter (1 shared paper)Luc F. Van Gaal (1 shared paper)Stephan Rössner (1 shared paper)Bernard Jandrain (3 shared papers)
In The Last Decade
Scheen Aj
54 papers receiving 583 citations
Peers
Comparison fields: 5 of 78
- Endocrinology, Diabetes and Metabolism 257
- Cardiology and Cardiovascular Medicine 199
- Pharmacology 144
- Endocrine and Autonomic Systems 44
- Transplantation 13
Countries citing papers authored by Scheen Aj
This map shows the geographic impact of Scheen Aj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scheen Aj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scheen Aj more than expected).
Fields of papers citing papers by Scheen Aj
This network shows the impact of papers produced by Scheen Aj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scheen Aj. The network helps show where Scheen Aj may publish in the future.
Co-authors
The 23 scholars most cited alongside Scheen Aj, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 208 | |
| 2 | 2004 | 167 | |
| 3 | [Chronopharmacology and chronotherapeutics]. | 1985 | 54 |
| 4 | 1999 | 51 | |
| 5 | [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk]. | 2015 | 13 |
| 6 | Retinopathy, but not neuropathy, is influenced by the level of residual endogenous insulin secretion in type 2 diabetes. | 1995 | 10 |
| 7 | [Obesity, insulin resistance and type 2 diabetes: risk factors for breast cancer]. | 2011 | 8 |
| 8 | 2005 | 7 | |
| 9 | [Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study]. | 2002 | 7 |
| 10 | 2000 | 5 | |
| 11 | [Type 2 diabetes: journey in the heart of a complex disease]. | 2012 | 5 |
| 12 | [Perspectives on atypical routes of insulin administration. Oral, rectal, and nasal routes]. | 1988 | 5 |
| 13 | [Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)]. | 2014 | 4 |
| 14 | [Clinical study of the month: ASTEROID: regression of coronary atherosclerosis with rosuvastatin at a maximal daily dose of 40 mg]. | 2006 | 4 |
| 15 | [Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?]. | 2011 | 4 |
| 16 | [Benefits and limitations of protein diets in obese patients with type 2 diabetes]. | 1999 | 3 |
| 17 | [Hypertension and diabetes: about a common but complex association]. | 2012 | 3 |
| 18 | 1991 | 3 | |
| 19 | [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes]. | 2016 | 3 |
| 20 | [LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY]. | 2016 | 3 |
About Scheen Aj
Scheen Aj is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology, Physiology, Surgery and Genetics, having authored 58 papers that have together received 619 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (18 papers), Diabetes Management and Research (10 papers), Diet and metabolism studies (9 papers), Pharmacology and Obesity Treatment (9 papers), Metabolism, Diabetes, and Cancer (4 papers), Lipoproteins and Cardiovascular Health (4 papers), Diabetes and associated disorders (3 papers) and Pharmaceutical Practices and Patient Outcomes (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (257 citations), Cardiology and Cardiovascular Medicine (199 citations), Pharmacology (144 citations), Endocrine and Autonomic Systems (44 citations) and Transplantation (13 citations). Scheen Aj has collaborated with scholars based in Belgium, France and Italy. Frequent co-authors include Nicolas Paquot, Marcelle Rorive, Nicolas Paquot, Michel Letiexhe, Philippe Schneiter, Luc F. Van Gaal, Stephan Rössner, Bernard Jandrain, Nathalie Esser and Olivier Ziegler. Their work appears in journals such as Diabetes & Metabolism, International Journal of Obesity, The Lancet, International Journal of Gynecology & Obstetrics and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.